

Andrew D Krahn

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6215242/publications.pdf>

Version: 2024-02-01

242
papers

13,568
citations

28274

55
h-index

24982

109
g-index

271
all docs

271
docs citations

271
times ranked

9681
citing authors

#	ARTICLE	IF	CITATIONS
1	HRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia Syndromes. <i>Heart Rhythm</i> , 2013, 10, 1932-1963.	0.7	1,587
2	2015 Heart Rhythm Society Expert Consensus Statement on the Diagnosis and Treatment of Postural Tachycardia Syndrome, Inappropriate Sinus Tachycardia, and Vasovagal Syncope. <i>Heart Rhythm</i> , 2015, 12, e41-e63.	0.7	694
3	Executive summary: HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. <i>Europace</i> , 2013, 15, 1389-1406.	1.7	494
4	2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. <i>Heart Rhythm</i> , 2019, 16, e301-e372.	0.7	494
5	Pacemaker or Defibrillator Surgery without Interruption of Anticoagulation. <i>New England Journal of Medicine</i> , 2013, 368, 2084-2093.	27.0	482
6	Randomized Assessment of Syncope Trial. <i>Circulation</i> , 2001, 104, 46-51.	1.6	423
7	Pacemaker Therapy in Patients With Neurally Mediated Syncope and Documented Asystole. <i>Circulation</i> , 2012, 125, 2566-2571.	1.6	380
8	Flecainide Therapy Reduces Exercise-Induced Ventricular Arrhythmias in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia. <i>Journal of the American College of Cardiology</i> , 2011, 57, 2244-2254.	2.8	352
9	Use of an Extended Monitoring Strategy in Patients With Problematic Syncope. <i>Circulation</i> , 1999, 99, 406-410.	1.6	330
10	Systematic Assessment of Patients With Unexplained Cardiac Arrest. <i>Circulation</i> , 2009, 120, 278-285.	1.6	280
11	Prevention of Syncope Trial (POST). <i>Circulation</i> , 2006, 113, 1164-1170.	1.6	256
12	Clinical Management of Catecholaminergic Polymorphic Ventricular Tachycardia. <i>Circulation</i> , 2015, 131, 2185-2193.	1.6	238
13	The Etiology of Syncope in Patients With Negative Tilt Table and Electrophysiological Testing. <i>Circulation</i> , 1995, 92, 1819-1824.	1.6	191
14	Arrhythmia characterization and long-term outcomes in catecholaminergic polymorphic ventricular tachycardia. <i>Heart Rhythm</i> , 2011, 8, 864-871.	0.7	171
15	Prevention of Arrhythmia Device Infection Trial. <i>Journal of the American College of Cardiology</i> , 2018, 72, 3098-3109.	2.8	160
16	Executive Summary: HRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia Syndromes. <i>Heart Rhythm</i> , 2013, 10, e85-e108.	0.7	159
17	Clinically Significant Pocket Hematoma Increases Long-Term Risk of Device Infection. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1300-1308.	2.8	154
18	Cost implications of testing strategy in patients with syncope. <i>Journal of the American College of Cardiology</i> , 2003, 42, 495-501.	2.8	150

#	ARTICLE	IF	CITATIONS
19	Predictors of Short-Term Complications After Implantable Cardioverter-Defibrillator Replacement. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2011, 4, 136-142.	4.8	143
20	Recommendations for the Use of Genetic Testing in the Clinical Evaluation of Inherited Cardiac Arrhythmias Associated with Sudden Cardiac Death: Canadian Cardiovascular Society/Canadian Heart Rhythm Society Joint Position Paper. <i>Canadian Journal of Cardiology</i> , 2011, 27, 232-245.	1.7	139
21	2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope: Executive Summary. <i>Journal of the American College of Cardiology</i> , 2017, 70, 620-663.	2.8	131
22	Utility of Treadmill Testing in Identification and Genotype Prediction in Long-QT Syndrome. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2010, 3, 120-125.	4.8	118
23	Cardiovascular disease and cancer: Evidence for shared disease pathways and pharmacologic prevention. <i>Atherosclerosis</i> , 2017, 263, 343-351.	0.8	118
24	Fludrocortisone for the Prevention of Vasovagal Syncope. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1-9.	2.8	116
25	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the state of genetic testing for cardiac diseases. <i>Europace</i> , 2022, 24, 1307-1367.	1.7	108
26	Diminishing proportional risk of sudden death with advancing age: implications for prevention of sudden death. <i>American Heart Journal</i> , 2004, 147, 837-840.	2.7	107
27	Sudden cardiac death despite an implantable cardioverter-defibrillator in a young female with catecholaminergic ventricular tachycardia. <i>Heart Rhythm</i> , 2006, 3, 1486-1489.	0.7	107
28	Inappropriate Sinus Tachycardia: Evaluation and Therapy. <i>Journal of Cardiovascular Electrophysiology</i> , 1995, 6, 1124-1128.	1.7	103
29	Sudden Cardiac Death Risk Stratification. <i>Circulation Research</i> , 2015, 116, 1907-1918.	4.5	100
30	Values and Preferences of Physicians and Patients With Nonvalvular Atrial Fibrillation Who Receive Oral Anticoagulation Therapy for Stroke Prevention. <i>Canadian Journal of Cardiology</i> , 2016, 32, 747-753.	1.7	97
31	Syncope clinical management in the emergency department: a consensus from the first international workshop on syncope risk stratification in the emergency department. <i>European Heart Journal</i> , 2016, 37, 1493-1498.	2.2	96
32	Implantable cardioverter-defibrillators in previously undiagnosed patients with catecholaminergic polymorphic ventricular tachycardia resuscitated from sudden cardiac arrest. <i>European Heart Journal</i> , 2019, 40, 2953-2961.	2.2	96
33	Diagnosis of Unexplained Cardiac Arrest. <i>Circulation</i> , 2005, 112, 2228-2234.	1.6	94
34	Risk Factors for Infections Involving Cardiac Implanted Electronic Devices. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2845-2854.	2.8	94
35	Quinidine, A Life-Saving Medication for Brugada Syndrome, Is Inaccessible in Many Countries. <i>Journal of the American College of Cardiology</i> , 2013, 61, 2383-2387.	2.8	86
36	The Emerging Role of Wearable Technologies in Detection of Arrhythmia. <i>Canadian Journal of Cardiology</i> , 2018, 34, 1083-1087.	1.7	85

#	ARTICLE	IF	CITATIONS
37	Hysteresis of the RT Interval With Exercise. <i>Circulation</i> , 1997, 96, 1551-1556.	1.6	85
38	Canadian Cardiovascular Society/Canadian Heart Rhythm Society 2016 Implantable Cardioverter-Defibrillator Guidelines. <i>Canadian Journal of Cardiology</i> , 2017, 33, 174-188.	1.7	84
39	Transethnic Genome-Wide Association Study Provides Insights in the Genetic Architecture and Heritability of Long QT Syndrome. <i>Circulation</i> , 2020, 142, 324-338.	1.6	83
40	Sudden Cardiac Death Prediction in Arrhythmogenic Right Ventricular Cardiomyopathy. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021, 14, e008509.	4.8	82
41	Outcome of the Fidelis implantable cardioverter-defibrillator lead advisory: A report from the Canadian Heart Rhythm Society Device Advisory Committee. <i>Heart Rhythm</i> , 2008, 5, 639-642.	0.7	79
42	Priorities for Emergency Department Syncope Research. <i>Annals of Emergency Medicine</i> , 2014, 64, 649-655.e2.	0.6	79
43	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the State of Genetic Testing for Cardiac Diseases. <i>Heart Rhythm</i> , 2022, 19, e1-e60.	0.7	78
44	Implantable cardioverter-defibrillator use in catecholaminergic polymorphic ventricular tachycardia: A systematic review. <i>Heart Rhythm</i> , 2018, 15, 1791-1799.	0.7	77
45	Genetic Testing in the Evaluation of Unexplained Cardiac Arrest. <i>Circulation: Cardiovascular Genetics</i> , 2017, 10, .	5.1	76
46	Age-Dependent Effect of β -Blockers in Preventing Vasovagal Syncope. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2012, 5, 920-926.	4.8	68
47	Cardiac Rehabilitation During the COVID-19 Era: Guidance on Implementing Virtual Care. <i>Canadian Journal of Cardiology</i> , 2020, 36, 1317-1321.	1.7	68
48	Syncope. <i>Circulation</i> , 2013, 127, 1330-1339.	1.6	65
49	Physiologic Pacing in Patients With Obstructive Sleep Apnea. <i>Journal of the American College of Cardiology</i> , 2006, 47, 379-383.	2.8	63
50	Detection of asymptomatic arrhythmias in unexplained syncope. <i>American Heart Journal</i> , 2004, 148, 326-332.	2.7	62
51	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population. <i>Europace</i> , 2020, 22, 1147-1148.	1.7	62
52	Predicting the Outcome of Patients with Unexplained Syncope Undergoing Prolonged Monitoring. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2002, 25, 37-41.	1.2	61
53	Precautions and Procedures for Coronary and Structural Cardiac Interventions During the COVID-19 Pandemic: Guidance from Canadian Association of Interventional Cardiology. <i>Canadian Journal of Cardiology</i> , 2020, 36, 780-783.	1.7	61
54	Insertable Loop Recorder Use for Detection of Intermittent Arrhythmias. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2004, 27, 657-664.	1.2	60

#	ARTICLE	IF	CITATIONS
55	Expert cardiologists cannot distinguish between Brugada phenocopy and Brugada syndrome electrocardiogram patterns. <i>Europace</i> , 2016, 18, 1095-1100.	1.7	57
56	Outcome of Apparently Unexplained Cardiac Arrest. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2016, 9, e003619.	4.8	56
57	Brugada syndrome and reduced right ventricular outflow tract conduction reserve: a final common pathway?. <i>European Heart Journal</i> , 2021, 42, 1073-1081.	2.2	56
58	Atrioventricular Node Reentry With "Smooth" AV Node Function Curves. <i>Circulation</i> , 1996, 93, 969-972.	1.6	55
59	Randomized Cluster Crossover Trials for Reliable, Efficient, Comparative Effectiveness Testing: Design of the Prevention of Arrhythmia Device Infection Trial (PADIT). <i>Canadian Journal of Cardiology</i> , 2013, 29, 652-658.	1.7	54
60	Short-coupled ventricular fibrillation represents a distinct phenotype among latent causes of unexplained cardiac arrest: a report from the CASPER registry. <i>European Heart Journal</i> , 2021, 42, 2827-2838.	2.2	54
61	Evaluation of Genes Encoding for the Transient Outward Current (Ito) Identifies the <i>KCNQ2</i> Gene as a Cause of J-Wave Syndrome Associated With Sudden Cardiac Death. <i>Circulation: Cardiovascular Genetics</i> , 2014, 7, 782-789.	5.1	53
62	Multicenter Emergency Department Validation of the Canadian Syncope Risk Score. <i>JAMA Internal Medicine</i> , 2020, 180, 737.	5.1	50
63	Epinephrine Infusion in the Evaluation of Unexplained Cardiac Arrest and Familial Sudden Death. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2012, 5, 933-940.	4.8	49
64	Cardiac Abnormalities in First-Degree Relatives of Unexplained Cardiac Arrest Victims. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2016, 9, .	4.8	48
65	Predicting heart failure decompensation using cardiac implantable electronic devices: a review of practices and challenges. <i>European Journal of Heart Failure</i> , 2016, 18, 977-986.	7.1	47
66	A novel RYR2 loss-of-function mutation (I4855M) is associated with left ventricular non-compaction and atypical catecholaminergic polymorphic ventricular tachycardia. <i>Journal of Electrocardiology</i> , 2017, 50, 227-233.	0.9	47
67	Beta blockers normalize QT hysteresis in long QT syndrome. <i>American Heart Journal</i> , 2002, 143, 528-534.	2.7	46
68	Procainamide infusion in the evaluation of unexplained cardiac arrest: From the Cardiac Arrest Survivors with Preserved Ejection Fraction Registry (CASPER). <i>Heart Rhythm</i> , 2014, 11, 1047-1054.	0.7	46
69	Myocarditis and Pericarditis After COVID-19 mRNA Vaccination: Practical Considerations for Care Providers. <i>Canadian Journal of Cardiology</i> , 2021, 37, 1629-1634.	1.7	45
70	An International Multicenter Evaluation of Inheritance Patterns, Arrhythmic Risks, and Underlying Mechanisms of <i>CASQ2</i> -Catecholaminergic Polymorphic Ventricular Tachycardia. <i>Circulation</i> , 2020, 142, 932-947.	1.6	44
71	Maturation of the Sensed Electrogram Amplitude Over Time in a New Subcutaneous Implantable Loop Recorder. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1997, 20, 1686-1690.	1.2	42
72	Ankyrin-B dysfunction predisposes to arrhythmogenic cardiomyopathy and is amenable to therapy. <i>Journal of Clinical Investigation</i> , 2019, 129, 3171-3184.	8.2	42

#	ARTICLE	IF	CITATIONS
73	Safe Reintroduction of Cardiovascular Services During the COVID-19 Pandemic. <i>Journal of the American College of Cardiology</i> , 2020, 75, 3177-3183.	2.8	41
74	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population. <i>Journal of Arrhythmia</i> , 2020, 36, 553-607.	1.2	40
75	Cost-Effectiveness of an Antibacterial Envelope for Cardiac Implantable Electronic Device Infection Prevention in the US Healthcare System From the WRAP-IT Trial. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020, 13, e008503.	4.8	39
76	An International Multicenter Evaluation of Type 5 Long QT Syndrome. <i>Circulation</i> , 2020, 141, 429-439.	1.6	39
77	Epidemiology of cardiac implantable electronic device infections: incidence and risk factors. <i>Europace</i> , 2021, 23, iv3-iv10.	1.7	38
78	Empiric pacemaker compared with a monitoring strategy in patients with syncope and bifascicular conduction block--rationale and design of the Syncope: Pacing or Recording in The Later Years (SPRITELY) study. <i>Europace</i> , 2012, 14, 1044-1048.	1.7	37
79	Clinical Presentation and Outcomes by Sex in Arrhythmogenic Right Ventricular Cardiomyopathy: Findings from the North American ARVC Registry. <i>Journal of Cardiovascular Electrophysiology</i> , 2016, 27, 555-562.	1.7	37
80	Midodrine for the Prevention of Vasovagal Syncope. <i>Annals of Internal Medicine</i> , 2021, 174, 1349-1356.	3.9	37
81	Importance of genetic testing in unexplained cardiac arrest. <i>European Heart Journal</i> , 2022, 43, 3071-3081.	2.2	36
82	Repolarization Dynamics During Exercise Discriminate Between LQT1 and LQT2 Genotypes. <i>Journal of Cardiovascular Electrophysiology</i> , 2010, 21, 1242-1246.	1.7	35
83	Duration of Electrocardiographic Monitoring of Emergency Department Patients With Syncope. <i>Circulation</i> , 2019, 139, 1396-1406.	1.6	35
84	Outcomes of untreated frequent premature ventricular complexes with normal left ventricular function. <i>Heart</i> , 2019, 105, 1408-1413.	2.9	34
85	Use of the Implantable Loop Recorder in Evaluation of Patients with Unexplained Syncope. <i>Journal of Cardiovascular Electrophysiology</i> , 2003, 14, S70-3.	1.7	33
86	Anticoagulation of patients on chronic warfarin undergoing arrhythmia device surgery: Wide variability of perioperative bridging in Canada. <i>Heart Rhythm</i> , 2009, 6, 1276-1279.	0.7	33
87	SCN5A mutations in 442 neonates and children: genotype-phenotype correlation and identification of higher-risk subgroups. <i>European Heart Journal</i> , 2018, 39, 2879-2887.	2.2	33
88	Evolution of clinical diagnosis in patients presenting with unexplained cardiac arrest or syncope due to polymorphic ventricular tachycardia. <i>Heart Rhythm</i> , 2014, 11, 274-281.	0.7	32
89	Comparison of Ajmaline and Procainamide Provocation Tests in the Diagnosis of Brugada Syndrome. <i>JACC: Clinical Electrophysiology</i> , 2019, 5, 504-512.	3.2	32
90	Arrhythmic risk prediction in arrhythmogenic right ventricular cardiomyopathy: external validation of the arrhythmogenic right ventricular cardiomyopathy risk calculator. <i>European Heart Journal</i> , 2022, 43, 3041-3052.	2.2	32

#	ARTICLE	IF	CITATIONS
91	Bridge or continue Coumadin for device surgery: a randomized controlled trial rationale and design. <i>Current Opinion in Cardiology</i> , 2009, 24, 82-87.	1.8	31
92	Arrhythmogenic Right Ventricular Cardiomyopathy. <i>JACC: Clinical Electrophysiology</i> , 2022, 8, 533-553.	3.2	31
93	Sentinel Symptoms in Patients with Unexplained Cardiac Arrest: From the Cardiac Arrest Survivors with Preserved Ejection Fraction Registry (CASPER). <i>Journal of Cardiovascular Electrophysiology</i> , 2012, 23, 60-66.	1.7	30
94	Effect of beta-blockers on QT dynamics in the long QT syndrome: measuring the benefit. <i>Europace</i> , 2014, 16, 1847-1851.	1.7	30
95	Preventing cardiac implantable electronic device infections. <i>Heart Rhythm</i> , 2015, 12, 2344-2356.	0.7	30
96	Clinical effectiveness of a systematic "pill-in-the-pocket" approach for the management of paroxysmal atrial fibrillation. <i>Heart Rhythm</i> , 2018, 15, 9-16.	0.7	30
97	Multilead QT Screening Is Necessary for QT Measurement. <i>JACC: Clinical Electrophysiology</i> , 2020, 6, 878-880.	3.2	30
98	Management of Ventricular Arrhythmias in Suspected Channelopathies. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2015, 8, 221-231.	4.8	29
99	Exercise and Inherited Arrhythmias. <i>Canadian Journal of Cardiology</i> , 2016, 32, 452-458.	1.7	28
100	Clinical and Functional Characterization of Ryanodine Receptor 2 Variants Implicated in Calcium-Release Deficiency Syndrome. <i>JAMA Cardiology</i> , 2022, 7, 84.	6.1	28
101	An International Multicenter Cohort Study on β -Blockers for the Treatment of Symptomatic Children With Catecholaminergic Polymorphic Ventricular Tachycardia. <i>Circulation</i> , 2022, 145, 333-344.	1.6	28
102	Congenital Long QT Syndrome. <i>JACC: Clinical Electrophysiology</i> , 2022, 8, 687-706.	3.2	28
103	Early repolarization is associated with symptoms in patients with type 1 and type 2 long QT syndrome. <i>Heart Rhythm</i> , 2014, 11, 1632-1638.	0.7	26
104	Experience with bisoprolol in long-QT1 and long-QT2 syndrome. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2016, 47, 163-170.	1.3	26
105	Brugada Syndrome. <i>JACC: Clinical Electrophysiology</i> , 2022, 8, 386-405.	3.2	26
106	Effect of Direct Oral Anticoagulants, Warfarin, and Antiplatelet Agents on Risk of Device Pocket Hematoma. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2019, 12, e007545.	4.8	25
107	Caring for the pregnant woman with an inherited arrhythmia syndrome. <i>Heart Rhythm</i> , 2020, 17, 341-348.	0.7	25
108	Canadian Cardiovascular Society Clinical Practice Update on the Assessment and Management of Syncope. <i>Canadian Journal of Cardiology</i> , 2020, 36, 1167-1177.	1.7	25

#	ARTICLE	IF	CITATIONS
109	Characterization of Myocardial Repolarization Reserve in Adolescent Females With Anorexia Nervosa. <i>Circulation</i> , 2016, 133, 557-565.	1.6	24
110	European Heart Rhythm Association (<scp>EHRA</scp>)/Heart Rhythm Society (<scp>HRS</scp>)/Asia Pacific Heart Rhythm Society (<scp>APHRS</scp>)/Latin American Heart Rhythm Society (<scp>LAHRS</scp>) Expert Consensus Statement on the state of genetic testing for cardiac diseases. <i>Journal of Arrhythmia</i> , 2022, 38, 491-553.	1.2	24
111	Rationale for the Assessment of Metoprolol in the Prevention of Vasovagal Syncope in Aging Subjects Trial (POST5). <i>American Heart Journal</i> , 2016, 174, 89-94.	2.7	23
112	Challenge and Impact of Quinidine Access in Sudden Death Syndromes. <i>JACC: Clinical Electrophysiology</i> , 2019, 5, 376-382.	3.2	23
113	Paradoxical impact of socioeconomic factors on outcome of atrial fibrillation in Europe: trends in incidence and mortality from atrial fibrillation. <i>European Heart Journal</i> , 2021, 42, 847-857.	2.2	23
114	Sex-Related Differences in Cardiac Channelopathies. <i>Circulation</i> , 2021, 143, 739-752.	1.6	23
115	Use of healthcare claims to validate the Prevention of Arrhythmia Device Infection Trial cardiac implantable electronic device infection risk score. <i>Europace</i> , 2021, 23, 1446-1455.	1.7	23
116	Râ€Wave Sensing in an Implantable Cardiac Monitor without ECGâ€Based Preimplant Mapping: Results from a Multicenter Clinical Trial. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2014, 37, 505-511.	1.2	22
117	The use of monitoring strategies in patients with unexplained syncope. <i>Clinical Autonomic Research</i> , 2004, 14, i55-i61.	2.5	21
118	Effect of Metoprolol on Quality of Life in the Prevention of Syncope Trial. <i>Journal of Cardiovascular Electrophysiology</i> , 2009, 20, 1083-1088.	1.7	20
119	Risk Factors for CIED Infection After Secondary Procedures. <i>JACC: Clinical Electrophysiology</i> , 2022, 8, 101-111.	3.2	20
120	Selecting Appropriate Diagnostic Tools for Evaluating the Patient With Syncope/Collapse. <i>Progress in Cardiovascular Diseases</i> , 2013, 55, 402-409.	3.1	19
121	Rationale and design of the randomized prospective ATLAS study: Avoid Transvenous Leads in Appropriate Subjects. <i>American Heart Journal</i> , 2019, 207, 1-9.	2.7	19
122	Acute Testing of the Rate-Smoothed Pacing Algorithm for Ventricular Rate Stabilization. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1999, 22, 554-561.	1.2	18
123	Mutation Location Effect on Severity of Phenotype During Exercise Testing in Type 1 Longâ€QT Syndrome: Impact of Transmembrane and Câ€Loop Location. <i>Journal of Cardiovascular Electrophysiology</i> , 2013, 24, 1015-1020.	1.7	18
124	Burst Exercise Testing Can Unmask Arrhythmias in Patients With Incompletely Penetrant Catecholaminergic Polymorphic Ventricular Tachycardia. <i>JACC: Clinical Electrophysiology</i> , 2021, 7, 437-441.	3.2	18
125	Defining idiopathic ventricular fibrillation: A systematic review of diagnostic testing yield in apparently unexplained cardiac arrest. <i>Heart Rhythm</i> , 2021, 18, 1178-1185.	0.7	18
126	Pregnancy in Catecholaminergic Polymorphic Ventricular Tachycardia. <i>JACC: Clinical Electrophysiology</i> , 2019, 5, 387-394.	3.2	17

#	ARTICLE	IF	CITATIONS
127	Differential calcium sensitivity in Na ^v 1.5 mixed syndrome mutants. <i>Journal of Physiology</i> , 2017, 595, 6165-6186.	2.9	16
128	Long COVID-19: A Primer for Cardiovascular Health Professionals, on Behalf of the CCS Rapid Response Team. <i>Canadian Journal of Cardiology</i> , 2021, 37, 1260-1262.	1.7	16
129	Detecting Underlying Cardiovascular Disease in Young Competitive Athletes. <i>Canadian Journal of Cardiology</i> , 2017, 33, 155-161.	1.7	15
130	Type 8 long QT syndrome: pathogenic variants in CACNA1C-encoded Cav1.2 cluster in STAC protein binding site. <i>Europace</i> , 2019, 21, 1725-1732.	1.7	15
131	Safe Reintroduction of Cardiovascular Services During the COVID-19 Pandemic. <i>Annals of Thoracic Surgery</i> , 2020, 110, 733-740.	1.3	15
132	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population. <i>Heart Rhythm</i> , 2020, 17, e269-e316.	0.7	15
133	Familial Evaluation in Idiopathic Ventricular Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021, 14, e009089.	4.8	15
134	Nothing inside the heart â€“ Combining epicardial pacing with the S-ICD. <i>HeartRhythm Case Reports</i> , 2015, 1, 419-423.	0.4	14
135	Sudden cardiac death: A reappraisal. <i>Trends in Cardiovascular Medicine</i> , 2016, 26, 709-719.	4.9	14
136	Evaluation of syncope: focus on diagnosis and treatment of neurally mediated syncope. <i>Expert Review of Cardiovascular Therapy</i> , 2016, 14, 725-736.	1.5	14
137	The Hearts in Rhythm Organization: A Canadian National Cardiogenetics Network. <i>CJC Open</i> , 2020, 2, 652-662.	1.5	14
138	Radiographic Predictors of Lead Conductor Fracture. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2014, 7, 1070-1077.	4.8	13
139	Recurrent syncope: differential diagnosis and management. <i>Heart</i> , 2015, 101, 1591-1599.	2.9	13
140	Safe Reintroduction of Cardiovascular Services During the COVID-19 Pandemic: From the North American Society Leadership. <i>Canadian Journal of Cardiology</i> , 2020, 36, 971-976.	1.7	13
141	Evaluation of age at symptom onset, proband status, and sex as predictors of disease severity in pediatric catecholaminergic polymorphic ventricular tachycardia. <i>Heart Rhythm</i> , 2021, 18, 1825-1832.	0.7	13
142	Design and Use of a Quantitative Scale for Measuring Presyncope. <i>Journal of Cardiovascular Electrophysiology</i> , 2009, 20, 888-893.	1.7	12
143	Arrhythmogenic Right Ventricular Cardiomyopathy With Recessive Inheritance Related to a New Homozygous Desmocollin-2 Mutation. <i>Canadian Journal of Cardiology</i> , 2014, 30, 696.e1-696.e3.	1.7	12
144	The QT Interval in Anorexia Nervosa. <i>JACC: Clinical Electrophysiology</i> , 2018, 4, 839-841.	3.2	12

#	ARTICLE	IF	CITATIONS
145	Acute Management of Ventricular Arrhythmia in Patients With Suspected Inherited Heart Rhythm Disorders. <i>JACC: Clinical Electrophysiology</i> , 2019, 5, 267-283.	3.2	12
146	The impact of steerable sheaths on unblinded contact force during catheter ablation for atrial fibrillation. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2020, 57, 417-424.	1.3	12
147	COVID-19 Pandemic: Global Impact and Potential Implications for Cardiovascular Disease in Canada. <i>CJC Open</i> , 2020, 2, 265-272.	1.5	12
148	In-hospital and long-term outcomes among patients with spontaneous coronary artery dissection presenting with ventricular tachycardia/fibrillation. <i>Heart Rhythm</i> , 2020, 17, 1864-1869.	0.7	12
149	Inherited Heart Rhythm Disease: Negotiating the Minefield for the Practicing Cardiologist. <i>Canadian Journal of Cardiology</i> , 2013, 29, 122-125.	1.7	11
150	Catheter ablation of atrial fibrillation in heart failure with reduced ejection fraction. <i>Journal of Cardiovascular Electrophysiology</i> , 2018, 29, 1049-1058.	1.7	11
151	The design and rationale of SAVE BC: The Study to Avoid Cardiovascular Events in British Columbia. <i>Clinical Cardiology</i> , 2018, 41, 888-895.	1.8	11
152	Shared Decision Making and the Cardiovascular Care of Athletes: Is It Time to Get Back in the Game?. <i>Canadian Journal of Cardiology</i> , 2020, 36, 941-944.	1.7	11
153	Cardiovascular Care Delivery During the Second Wave of COVID-19 in Canada. <i>Canadian Journal of Cardiology</i> , 2021, 37, 790-793.	1.7	11
154	Biventricular pacing improves quality of life and exercise tolerance in patients with heart failure and intraventricular conduction delay. <i>Canadian Journal of Cardiology</i> , 2002, 18, 380-7.	1.7	11
155	A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Efficacy and Safety of Intravenously Administered Dofetilide in Patients with Wolff-Parkinson-White Syndrome. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2001, 24, 1258-1260.	1.2	10
156	Recognizing Life-Threatening Causes of Syncope. <i>Cardiology Clinics</i> , 2013, 31, 51-66.	2.2	10
157	Anticoagulation for Thromboembolic Risk Reduction in Adults With Congenital Heart Disease. <i>Canadian Journal of Cardiology</i> , 2017, 33, 1597-1603.	1.7	10
158	Concomitant anti-platelet therapy in warfarin-treated patients undergoing cardiac rhythm device implantation: A secondary analysis of the BRUISE CONTROL trial. <i>International Journal of Cardiology</i> , 2019, 288, 87-93.	1.7	10
159	Establishing reference ranges for ambulatory electrocardiography parameters: meta-analysis. <i>Heart</i> , 2020, 106, 1732-1739.	2.9	10
160	Heart Rate Recovery After Exercise Is Associated With Arrhythmic Events in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020, 13, e007471.	4.8	10
161	Variant Reinterpretation in Survivors of Cardiac Arrest With Preserved Ejection Fraction (the Cardiac Tj ETQq1 1 0.784314 rgBT /Over Laboratories. <i>Circulation Genomic and Precision Medicine</i> , 2021, 14, e003235.	3.6	10
162	Predictors of perforation during lead extraction: Results of the Canadian Lead ExtrAction Risk (CLEAR) study. <i>Heart Rhythm</i> , 2022, 19, 1097-1103.	0.7	10

#	ARTICLE	IF	CITATIONS
163	Atrial arrhythmias and thromboembolic complications in adults post Fontan surgery. <i>Open Heart</i> , 2020, 7, e001224.	2.3	10
164	Should patients with asymptomatic wolff-parkinson-white pattern undergo a catheter ablation?. <i>Current Cardiology Reports</i> , 2001, 3, 301-304.	2.9	9
165	A Detailed Description and Assessment of Outcomes of Patients With Hospital Recorded QTc Prolongation. <i>American Journal of Cardiology</i> , 2015, 115, 907-911.	1.6	9
166	Reduced Uptake of Family Screening in Genotypeâ€Negative Versus Genotypeâ€Positive Long QT Syndrome. <i>Journal of Genetic Counseling</i> , 2015, 24, 558-564.	1.6	9
167	A Systematic Review of the Risk of Motor Vehicle Collision in Patients With Syncope. <i>Canadian Journal of Cardiology</i> , 2021, 37, 151-161.	1.7	9
168	Progressive Anterior Ablation in the Coronary Sinus Region. <i>Circulation</i> , 1997, 96, 3477-3483.	1.6	9
169	Delivery of Peer Support Through a Self-Management mHealth Intervention (Healing Circles) in Patients With Cardiovascular Disease: Protocol for a Randomized Controlled Trial. <i>JMIR Research Protocols</i> , 2019, 8, e12322.	1.0	9
170	Cost of Preimplantation Cardiac Imaging in Patients Referred for a Primary-Prevention Implantable Cardioverter-Defibrillator. <i>American Journal of Cardiology</i> , 2008, 102, 588-592.	1.6	8
171	Risk score for the exclusion of arrhythmic events in arrhythmogenic right ventricular cardiomyopathy at first presentation. <i>International Journal of Cardiology</i> , 2019, 290, 100-105.	1.7	8
172	The Utility of Holter Monitoring Compared to Loop Recorders in the Evaluation of Syncope and Presyncope. <i>Annals of Noninvasive Electrocardiology</i> , 2000, 5, 284-289.	1.1	7
173	Effectiveness of medical therapy for treatment of idiopathic frequent premature ventricular complexes. <i>Journal of Cardiovascular Electrophysiology</i> , 2021, 32, 2246-2253.	1.7	7
174	Post-operative pain following cardiac implantable electronic device implantation: insights from the BRUISE CONTROL trials. <i>Europace</i> , 2021, 23, 748-756.	1.7	7
175	The Canadian Arrhythmogenic Right Ventricular Cardiomyopathy Registry: Rationale, Design, and Preliminary Recruitment. <i>Canadian Journal of Cardiology</i> , 2016, 32, 1396-1401.	1.7	6
176	Feasibility of tricuspid valve-in-valve replacement in a patient with transvalvular pacemaker. <i>HeartRhythm Case Reports</i> , 2016, 2, 2-5.	0.4	6
177	Early Repolarization Pattern Inheritance in the Cardiac Arrest Survivors With Preserved Ejection Fraction Registry (CASPER). <i>JACC: Clinical Electrophysiology</i> , 2018, 4, 1473-1479.	3.2	6
178	Switching Between Î²-Blockers: An Empiric Tool for the Cardiovascular Practitioner. <i>Canadian Journal of Cardiology</i> , 2019, 35, 539-543.	1.7	6
179	Anticoagulation for Patients With Atrial Fibrillation and End-Stage Renal Disease on Dialysis: A National Survey. <i>Canadian Journal of Cardiology</i> , 2021, 37, 924-928.	1.7	6
180	Guidance for Rebooting Electrophysiology Through the COVID-19 Pandemic From the Heart Rhythm Society and the American Heart Association Electrocardiography and Arrhythmias Committee of the Council on Clinical Cardiology. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020, 13, e008999.	4.8	6

#	ARTICLE	IF	CITATIONS
181	Loop recorders for syncope evaluation: what is the evidence?. <i>Expert Review of Medical Devices</i> , 2016, 13, 1021-1027.	2.8	5
182	The accessibility and utilization of genetic testing for inherited heart rhythm disorders: a Canadian cross-sectional survey study. <i>Journal of Community Genetics</i> , 2018, 9, 257-262.	1.2	5
183	Changes on the electrocardiogram in anorexia nervosa: A case control study. <i>Journal of Electrocardiology</i> , 2019, 56, 64-69.	0.9	5
184	Driving Restrictions and Early Arrhythmias in Patients Receiving a Primary-Prevention Implantable Cardioverter-Defibrillator (DREAM-ICD) Study. <i>Canadian Journal of Cardiology</i> , 2020, 36, 1269-1277.	1.7	5
185	Size matters in atrial fibrillation: the underestimated importance of reduction of contiguous electrical mass underlying the effectiveness of catheter ablation. <i>Europace</i> , 2021, 23, 1698-1707.	1.7	5
186	Management of Congenital Long-QT Syndrome: Commentary From the Experts. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021, 14, e009726.	4.8	5
187	Caffeinated energy drinks in the Canadian context: health risk assessment with a focus on cardiovascular effects. <i>Applied Physiology, Nutrition and Metabolism</i> , 2021, 46, 1019-1028.	1.9	5
188	Early Repolarisation “ What Should the Clinician Do?. <i>Arrhythmia and Electrophysiology Review</i> , 2015, 04, 96.	2.4	5
189	Does any therapy really work for neurocardiogenic syncope?. <i>Cardiology Journal</i> , 2014, 21, 616-624.	1.2	5
190	Effects of caffeinated energy drinks on cardiovascular responses during exercise in healthy adults: a systematic review and meta-analysis of randomized controlled trials. <i>Applied Physiology, Nutrition and Metabolism</i> , 2022, 47, 618-631.	1.9	5
191	Canadian Registry of Implantable Electronic Device Outcomes: Longer-term follow-up of the Riata lead under advisory. <i>Heart Rhythm</i> , 2018, 15, 524-529.	0.7	4
192	Brugada Syndrome: Clinical Care Amidst Pathophysiological Uncertainty. <i>Heart Lung and Circulation</i> , 2020, 29, 538-546.	0.4	4
193	Heart failure treatment in patients with cardiac implantable electronic devices: Opportunity for improvement. <i>Heart Rhythm O2</i> , 2021, 2, 698-709.	1.7	4
194	Life threatening causes of syncope: Channelopathies and cardiomyopathies. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2014, 184, 53-59.	2.8	3
195	Impact of generator replacement on the risk of Fidelis lead fracture. <i>Heart Rhythm</i> , 2016, 13, 1618-1623.	0.7	3
196	Fast and spurious: Correcting the QT interval. <i>Heart Rhythm</i> , 2016, 13, 536-537.	0.7	3
197	Cost Analysis of Patients Referred for Inherited Heart Rhythm Disorder Evaluation. <i>Canadian Journal of Cardiology</i> , 2017, 33, 814-821.	1.7	3
198	Quinidine effective for the management of ventricular and atrial arrhythmias associated with Brugada syndrome. <i>HeartRhythm Case Reports</i> , 2018, 4, 270-272.	0.4	3

#	ARTICLE	IF	CITATIONS
199	The importance of a comprehensive evaluation of survivors of cardiac arrest. <i>European Heart Journal</i> , 2018, 39, 1988-1991.	2.2	3
200	Use of Renin-Angiotensin System Blockers During the COVID-19 Pandemic: Early Guidance and Evolving Evidence. <i>Canadian Journal of Cardiology</i> , 2020, 36, 1180-1182.	1.7	3
201	Changes to the electrocardiogram during exercise in anorexia nervosa. <i>Journal of Electrocardiology</i> , 2020, 61, 99-105.	0.9	3
202	Patch monitors for arrhythmia monitoring in patients for suspected inherited arrhythmia syndrome. <i>Journal of Cardiovascular Electrophysiology</i> , 2021, 32, 856-859.	1.7	3
203	Implantable Cardioverter Defibrillator Lead Survival in Athletic Patients. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021, 14, e009344.	4.8	3
204	Pregnancy in catecholaminergic polymorphic ventricular tachycardia: therapeutic optimization and multidisciplinary care are key to success. <i>Herzschrittmachertherapie Und Elektrophysiologie</i> , 2021, 32, 199-206.	0.8	3
205	Return of Results Policies for Genomic Research: Current Practices and the Hearts in Rhythm Organization (HiRO) Approach. <i>Canadian Journal of Cardiology</i> , 2022, 38, 526-535.	1.7	3
206	Inheritance of Early Repolarization and Familial Malignant Forms. <i>Journal of the American College of Cardiology</i> , 2013, 61, 173-175.	2.8	2
207	Review of Eligibility for Cardiac Resynchronization Therapy. <i>American Journal of Cardiology</i> , 2015, 116, 318-324.	1.6	2
208	Response to Letters Regarding Article, "Clinical Management of Catecholaminergic Polymorphic Ventricular Tachycardia: The Role of Left Cardiac Sympathetic Denervation." <i>Circulation</i> , 2016, 133, e366-7.	1.6	2
209	Assessing arrhythmia risk in a 15-year-old boy whose father died suddenly. <i>Cmaj</i> , 2016, 188, 1172-1174.	2.0	2
210	Differentiating Ventricular From Supraventricular Arrhythmias Using the Postpacing Interval After Failed Antitachycardia Pacing. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2018, 11, e005921.	4.8	2
211	Canadian Registry of Implantable Electronic Device Outcomes: Surveillance of High-Voltage Leads. <i>Canadian Journal of Cardiology</i> , 2018, 34, 808-811.	1.7	2
212	Letter by Cheung et al Regarding Article, "Concealed Arrhythmogenic Right Ventricular Cardiomyopathy in Sudden Unexplained Cardiac Death Events." <i>Circulation Genomic and Precision Medicine</i> , 2019, 12, e002447.	3.6	2
213	Genetic Testing in Inherited Arrhythmias: Approach, Limitations, and Challenges. <i>Canadian Journal of Cardiology</i> , 2020, 36, 584-587.	1.7	2
214	The merits of the ICD for inherited heart rhythm disorders: A critical re-appraisal. <i>Trends in Cardiovascular Medicine</i> , 2020, 30, 415-421.	4.9	2
215	Guiding Cardiac Care During the COVID-19 Pandemic: How Ethics Shapes Our Health System Response. <i>Canadian Journal of Cardiology</i> , 2020, 36, 1313-1316.	1.7	2
216	SCN5A α 683R exhibits combined gain-of-function and loss-of-function properties related to adrenaline-triggered ventricular arrhythmia. <i>Experimental Physiology</i> , 2021, 106, 683-699.	2.0	2

#	ARTICLE	IF	CITATIONS
217	Canadian Registry of Electronic Device Outcomes: remote monitoring outcomes in the Abbott battery performance alert—a multicentre cohort. <i>Europace</i> , 2021, 23, 1319-1323.	1.7	2
218	The clinical utility of procainamide-induced late potentials on the signal averaged ECG. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2021, 44, 2046-2053.	1.2	2
219	Bluetooth-enabled implantable cardiac monitors and two-way smartphone communication for patients with hypertrophic cardiomyopathy. <i>CJC Open</i> , 2021, 4, 305-314.	1.5	2
220	DREAM-ICD-II Study. <i>Circulation</i> , 2022, 145, 742-753.	1.6	2
221	Latent Causes of Sudden Cardiac Arrest. <i>JACC: Clinical Electrophysiology</i> , 2022, 8, 806-821.	3.2	2
222	To Pace or Not to Pace?. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1995, 18, 1584-1585.	1.2	1
223	Catecholaminergic Polymorphic Ventricular Tachycardia. <i>JACC: Clinical Electrophysiology</i> , 2016, 2, 263-265.	3.2	1
224	Response by Thiruganasambandamoorthy et al to Letters Regarding Article, “Duration of Electrocardiographic Monitoring of Emergency Department Patients With Syncope” <i>Circulation</i> , 2019, 140, e655-e656.	1.6	1
225	Canadian Registry of Electronic Device Outcomes (CREDO): The Abbott ICD Premature Battery Depletion Advisory, a Multicentre Cohort Study. <i>CJC Open</i> , 2021, 3, 48-53.	1.5	1
226	Effectiveness of a simple medication adjustment protocol for optimizing peri-cardioversion rate control: A derivation and validation cohort study. <i>Heart Rhythm O2</i> , 2021, 2, 46-52.	1.7	1
227	Cardiac Implantable Devices Management in Medical Assistance in Dying (MAiD): Review and Recommendations for Cardiac Device Clinics. <i>Canadian Journal of Cardiology</i> , 2021, 37, 1648-1650.	1.7	1
228	Exercise Testing With Flecainide Demonstrates Provocable Brugada Syndrome. <i>CJC Open</i> , 2021, 3, 1079-1081.	1.5	1
229	Quinidine vs. ICD therapy in short-coupled ventricular fibrillation—is a randomized trial the next logical step?. <i>European Heart Journal</i> , 2021, 42, 3993-3994.	2.2	1
230	A Population-Based Study of Unexplained/Lone Atrial Fibrillation: Temporal Trends, Management, and Outcomes. <i>CJC Open</i> , 2022, 4, 65-74.	1.5	1
231	Cardiomyopathy Genes and Idiopathic VF: A Known Unknown?. <i>Circulation Genomic and Precision Medicine</i> , 2022, 15, CIRCGEN122003680.	3.6	1
232	A Case of Rate Dependent Accessory Pathway Conduction. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1995, 18, 1448-1449.	1.2	0
233	Opening Pandora's Box — incidental genetic findings. <i>Nature Reviews Cardiology</i> , 2016, 13, 187-188.	13.7	0
234	The Resilience of Women: Atrial Fibrillation Resistance. <i>Journal of Cardiovascular Electrophysiology</i> , 2016, 27, 1030-1031.	1.7	0

#	ARTICLE	IF	CITATIONS
235	Learning to Make Decisions: Are Medical Postgraduate Trainees Getting With the Atrial Fibrillation Guidelines?. Canadian Journal of Cardiology, 2016, 32, 714-716.	1.7	0
236	My Approach to the patient with a borderline long QT interval. Trends in Cardiovascular Medicine, 2017, 27, 516-517.	4.9	0
237	A longer look at preventing cardiac device infection. Heart Rhythm, 2020, 17, 1123-1124.	0.7	0
238	A Focus on COVID-19: Fast and Accurate Information to Guide Management for Pandemic-Related Issues in Cardiac Patients. Canadian Journal of Cardiology, 2020, 36, 787-788.	1.7	0
239	Watch Carefully. Journal of the American College of Cardiology, 2020, 75, 1363-1364.	2.8	0
240	Documenting the descent “ remote monitoring and adult-onset Catecholaminergic Polymorphic Ventricular Tachycardia associated with ventricular fibrillation and bradycardia. Cardiology in the Young, 2021, 31, 1330-1332.	0.8	0
241	Process of Care and a Practical Toolkit for Evaluating and Managing Arrhythmic Risk in the Cardiogenetic Pregnant Patient. Canadian Journal of Cardiology, 2021, , .	1.7	0
242	Bradycardias and Tachycardias: Acquired and Inheritable. , 2020, , 109-123.		0